reolysin

I deleted my previous post because the link I gave (which takes you to the on-line version of the UK Daily Express newspaper) brought lots of pop-ups. To by-pass the pop ups, I'm pasting the article below.
The article is about a trial for reolysin and it seemed interesting because included lung cancer patients.

"A "MAGIC bullet" cancer drug that blasts away tumours could bring hope to thousands of sufferers currently given no chance of survival.
Experts have hailed the new drug, made from a harmless bug that can cause stomach upsets, as a major new weapon in the battle to find a cure for cancer.
Early evidence from a trial carried out in patients with advanced, untreatable cancers who had stopped benefiting from radiotherapy has seen remarkable results.
The simple injection has stopped the spreading of the deadly disease in its tracks and has even successfully reversed its growth.
In one remarkable case, a man who had a large tumour mass saw it shrink enough to be surgically removed. Another patient with the most deadly form of skin cancer which had spread was still alive 17 months after treatment started.
Study leader Dr Kevin Harrington from the Institute of Cancer Research in London said: “A magic bullet depends on how you would define a magic bullet, but if you mean a treatment that can kill cancer cells and leave normal cells unscathed, then it has that property.”
The common virus is injected into patients and boosts their immune systems, blasting away tumours.
Used alongside radiotherapy, it creates a potent combination that makes the disease more treatable. The virus is commonly found in human respiratory and gastrointestinal tracts, with no symptoms apart from mild stomach upsets.
A new drug, called Reolysin, contains the virus particles. It is hoped it will provide the longed-for “magic bullet” to kill off the disease. Early results have shown it can do so in some cases and can prolong the life of patients given just a short time to live.
The pilot clinical trial, conducted in the UK, shows that Reolysin has the power to combat advanced cancers. It has already been shown in laboratory tests to magnify the effects of radiotherapy. It appears to work by rupturing the walls of cancer cells, creating a chain reaction of small “explosions” that rip the tumours apart. As they shrink, they become more susceptible to radiotherapy treatment.
It also seems to boost the immune system, recognising cancer cells as invaders and allowing the body to mount its own attack against them.
The Phase I trial, funded by Oncolytics Biotech Inc, Canadian manufacturers of Reolysin, involved 23 patients with a range of solid tumours including lung, bowel, ovarian and skin cancers. All had stopped responding to traditional therapies. They were given between two and six injections of Reolysin in escalating doses, combined with low or high-dose radiotherapy.
The main aim was to test whether the treatment was safe, but researchers also measured tumour responses for 14 patients. In every case, tumours either shrank or stopped growing, the scientists reported in the journal Clinical Cancer Research. Tumours shrank in two patients and stabilised in five who received low-dose radiotherapy.
Of seven patients on high-dose radiotherapy, tumours shrank in five cases and stabilised in two. One patient had a large tumour mass in a salivary gland which was reduced in size enough to be surgically removed. Another who was close to death with a serious form of spreading skin cancer was still alive 17 months later. Side effects were mild.
The next step will be to investigate effects in patients with newly-diagnosed cancers that would normally be treated with radiotherapy alone.
Dr Brad Thompson, president and chief executive of Oncolytics Biotech Inc, said: “We believe this study demonstrates that the combination of low-dose radiation and Reolysin is well tolerated and that the very high response rate warrants further investigation.”
Dr Joanna Owens, science information manager at Cancer Research UK, said: “While these results are encouraging, it’s important to stress that this treatment has been tested in only a handful of patients so far.” "

Report post

7 replies. Join the discussion

If anyone is interested, there are clinical trials in the US. Go to the link below and enter Reolysin in search. Many are accepting participants. Good luck and take care, JC
http://www.clinicaltrials.gov/

Report post

Wow. Thanks AliceW. It's good to know there's something new around the corner that just might just knock this thing on the head! Wouldn't it be great!

We all just have to last long enough to be able to take advantage of it. And Why Not?

Thank you for sharing this information.

Report post

New video from San Antonio Cancer Therapy Research Center. I've said this before Reolysin is the read deal for multiple metastatic cancer types:

http://www.foxsanantonio.com/newsroom/top_stories/videos/vid_2266.shtml

Report post

Another interesting new treatment - there really does seem to be a lot of choices these days!
*note - pop-ups don't scare me and my Firefox! :)

Report post

http://www.jci.org/articles/view/41431?key=1ec1c381a8cdc1939fa9

More on Reolysin - the above is a new article about pre-clinical (mouse model) testing of Reolysin in combination with an antiangiogenisis drug. It is a very long article and highly scientific but bottom line "Importantly, because this combinatorial approach targets the tumor endothelium, these data have direct, wide-ranging, and immediate clinical applicability across a broad range of tumor types using reagents that are already approved for use in patients. "

They will have to test this combination on people in the clinic. This appears to indicate that anti-angiogenisis drugs in combination with Reolysin may work synergystically (the combination is better than either by itself) in treating multiple tiumor types. They already know that Reolysin works synergystically with Taxanes and the platinum drugs Cysplatin\Carbplatin, and gemciabine. They first proved this in pre-clinical trials with mice and then proved it in clinical trials with cancer patients. The company also just announced a trial of Reolysin with FOLFIRI (colorectal cancer).

http://www.integratir.com/newsrelease.asp?news=2131023383&ticker=T.ONC&lang =EN&ny=on

They are also getting exceptional results with the Reolysine in combination with Radiation Therapy.

http://www.integratir.com/newsrelease.asp?news=2131023378&ticker=T.ONC&lang =EN&ny=on

Here is general information about Reolysin:
Drug is only available in clinical trials. It is still not a proven therapy and it will take a few years yet before it becomes a product if approved by the FDA - big IF.
Multiple PI, PII, PIII trials are on-going
Direct injection into tumors or intravenous delivery
Reolysin treats multiple cancer types
Reolysin works best and synergystically when used in combination with existing chemo and radiation therapies.

Angeldog

Report post

A number of Reolysin trials are\have been held in Great Britain where Reolysin has gotten good press. Here are two articles came out today. The first one reminds everyone the Reolysin is experimental and the second one explains Reolysin. They are both from CancerResearchUK:

http://scienceblog.cancerresearchuk.org/2010/06/01/experimental-virus-treat ment-is-still-in-development/

http://www.cancerhelp.org.uk/about-cancer/cancer-questions/what-is-reolysin -treatment#available

Report post

This discussion is closed to replies. We close all discussions after 90 days.

If there's something you'd like to discuss, click below to start a new discussion.

Photo of Dave Grant

The Lung Cancer Survivors Support Community has provided support for patients, caregivers, families and friends since 2006. We welcome over 600 new members every month in the fight against lung cancer.

ALK mutations and lung cancer

Join the discussion about ALK mutations and lung cancer

Things you can do

Discussion topics

Community leaders